1993
DOI: 10.1073/pnas.90.24.11683
|View full text |Cite
|
Sign up to set email alerts
|

Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.

Abstract: Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain ABSTRACTUsing the process of "antibody antigenization," we engineered two antibody molecules carrying in the third complementarity-determining region of the heavy chain variable domain a 7-mer or a 15-mer peptide epitope ofthe first extraceliular domain (D1) of human CD4 receptor-namely, Ser-Phe-Leu-Thr-Lys-Gly-Pro-Ser (SFLTKGPS; positions 42 through 49) and Gly-Ser-Phe-Leu-Thr-Lys-G… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0

Year Published

1995
1995
2014
2014

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 48 publications
0
7
0
Order By: Relevance
“…The approach of using a protein of known three-dimensional structure to present active sequences in a constrained and structurally defined conformation has already been addressed by other groups. However, in all published examples much larger proteins have been used; immunoglobulin (150 kDa) (37)(38)(39)(40), alkaline phosphatase (121 kDa) (41), interleukin 1,3 (17 kDa) (40,42,43), staphylococcal nuclease (17 kDa) (44), lysozyme (15 kDa) (45,46), and the exogenous sequences have been invariably inserted on exposed loop regions. A newly designed shorter version of the immunoglobulin fold, the minibody (7 kDa) (27), has also been designed and again the loop region was engineered.…”
Section: Methodsmentioning
confidence: 99%
“…The approach of using a protein of known three-dimensional structure to present active sequences in a constrained and structurally defined conformation has already been addressed by other groups. However, in all published examples much larger proteins have been used; immunoglobulin (150 kDa) (37)(38)(39)(40), alkaline phosphatase (121 kDa) (41), interleukin 1,3 (17 kDa) (40,42,43), staphylococcal nuclease (17 kDa) (44), lysozyme (15 kDa) (45,46), and the exogenous sequences have been invariably inserted on exposed loop regions. A newly designed shorter version of the immunoglobulin fold, the minibody (7 kDa) (27), has also been designed and again the loop region was engineered.…”
Section: Methodsmentioning
confidence: 99%
“…Previously, we demonstrated flowcytometry-reactive antibodies to human CD4 in a high proportion (75 %) of cases [24]. We conclude that the physical characteristics of a given receptor peptide (e.g., length, hydrophilicity, etc.)…”
Section: Discussionmentioning
confidence: 51%
“…In previous work from this laboratory we demonstrated the induction of anti-receptor immunity using immunoglobulins (Ig) expressing discrete peptide portions of human CD4 [24]. We refer to such Ig as antigenized antibodies, i.e ., Ig molecules in which foreign peptide sequences are conformationally-constrained and expressed in the complementority-determining region (CDR) loops [25].…”
Section: Introductionmentioning
confidence: 99%
“…This provides the structural basis of IG variable domain antigenicity that could reside in the FR (public) or CDR (private), termed as idiotype. Indeed, viral T and B cell epitopes [37,38], parasitic B cell epitope [33] and CD4 molecule [39] have been used to antigenize IG that induced specific immune response subsequent to immunization. In this context, it is important to note that genetic imprints of all antigens present in the universe (10 8 −10 11 ) are enshrined within the framework of "internal mirror image" as idiotype in the antibody repertoire.…”
Section: Designing Antibody Fragments Of Desired Functionmentioning
confidence: 99%